Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib

We describe the first report case associated with vandetanib, a tyrosine kinase inhibitor indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (CMT) in patients with locally advanced or metastatic non-resectable disease.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research